Literature DB >> 9237030

High-dose diltiazem prevents migration and proliferation of vascular smooth muscle cells in various in-vitro models of human coronary restenosis.

R Voisard1, S Koschnick, R Baur, U Vogel, T Mattfeldt, W Hemmer, A Hannekum, M Höher, V Hombach.   

Abstract

BACKGROUND: Restenosis after coronary angioplasty is considered to be caused mainly by increased migration and proliferation of smooth muscle cells (SMC). The concept of local, site-specific delivery of pharmacologic therapies has opened the door for new, high-dose drug regimes. METHODS AND
RESULTS: SMC were isolated by enzymatic disaggregation with collagenase/elastase from human coronary plaque tissue of 29 patients (pSMC) and post mortem from the coronary media of 33 corpses (mSMC). Endothelial cells were isolated from human umbilical veins by enzymatic disaggregation with collagenase/dispase. By positive reaction with antibodies against smooth muscle alpha-actin and von Willebrand factor cells were identified as SMC or endothelial cells. In proliferation studies 5-150 micrograms/ml diltiazem was added to the culture media of pSMC, mSMC and endothelial cells. After 5 days there was a significant dose-dependent inhibition of cell proliferation (for pSMC with > 50 micrograms/ml, for mSMC with > 25 micrograms/ml, and for endothelial cells with > 5 micrograms/ml). In migration studies the effect of 5-150 micrograms/ml diltiazem on the velocity of migration of pSMC was investigated over a period of 48 h. Administration of diltiazem at concentrations of 100 and 150 micrograms/ml caused a significant inhibition of the migration of pSMC. The cytoskeletal components smooth muscle alpha-actin, vimentin, and alpha-tubulin of pSMC and the expression of von Willebrand factor of endothelial cells were investigated after an incubation period of 5 days with 50 and 150 micrograms/ml diltiazem. In the transfilter coculture model the effect of 50 micrograms/ml diltiazem on mSMC was investigated after mechanical injury of cocultured endothelial cells. Administration of diltiazem at a concentration of 50 micrograms/ml inhibited the development of a neointimal proliferate in the transfilter coculture model significantly (P < 0.001).
CONCLUSIONS: A high dose of diltiazem inhibited the migratory and proliferative activities of coronary SMC significantly. In further experimental studies the effect of locally applied high doses of diltiazem on postangioplasty restenosis should be elucidated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237030     DOI: 10.1097/00019501-199703000-00011

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  6 in total

1.  [Calcium channel blocker diltizem transiently inhibits migration and up-regulates metadherin expression in hepatocellular carcinoma cells in vitro].

Authors:  Rui Guo; Xueyuan Jin; Yi Tian; Xiaozhong Huang; Zongfang Li; Jun Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-03-30

2.  Effect of Anti-Hypertensive Medication History on Arteriovenous Fistula Maturation Outcomes.

Authors:  Ke Wang; Leila R Zelnick; Peter B Imrey; Ian H deBoer; Jonathan Himmelfarb; Michael D Allon; Alfred K Cheung; Laura M Dember; Prabir Roy-Chaudhury; Miguel A Vazquez; John W Kusek; Harold I Feldman; Gerald J Beck; Bryan Kestenbaum
Journal:  Am J Nephrol       Date:  2018-08-02       Impact factor: 3.754

3.  Simultaneous intra/extravascular administration of antiproliferative agents as a new strategy to inhibit restenosis: the peak of reactive cell proliferation as a hallmark for the duration of the treatment.

Authors:  Rainer Voisard; Eva Kucharczyk; Ute Deininger; Regine Baur; Vinzenz Hombach
Journal:  BMC Cardiovasc Disord       Date:  2002-01-18       Impact factor: 2.298

4.  The effects of prior calcium channel blocker therapy on creatine kinase-MB levels after percutaneous coronary interventions.

Authors:  Oyku Gulmez; Ilyas Atar; Bülent Ozin; Mehmet Emin Korkmaz; Asli Atar; Alp Aydinalp; Aylin Yildirir; Haldun Muderrisoglu
Journal:  Vasc Health Risk Manag       Date:  2008

5.  Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratios.

Authors:  Rainer Voisard; Svenja Zellmann; Fabian Müller; Felicitas Fahlisch; Lutz von Müller; Regine Baur; Jürgen Braun; Jürgen Gschwendt; Margaratis Kountides; Vinzenz Hombach; Joachim Kamenz
Journal:  BMC Cardiovasc Disord       Date:  2007-05-11       Impact factor: 2.298

6.  Panaxquin quefolium diolsaponins dose-dependently inhibits the proliferation of vascular smooth muscle cells by downregulating proto-oncogene expression.

Authors:  Zhihao Wang; Yingkai Wang; Xuezhong Zhao
Journal:  Indian J Pharmacol       Date:  2013 Sep-Oct       Impact factor: 1.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.